biosyn Arzneimittel GmbH announces Pascal Voltzenlugel as Managing Director/CEO – ensuring positive development.
Fellbach, November 1st 2023 – At the shareholders’ meeting of biosyn Arzneimittel GmbH, Pascal Voltzenlugel was appointed as the new Managing Director and CEO of the company. This key decision marks a significant milestone for biosyn and is seen as a decisive step towards the positive development of the company.
Pascal Voltzenlugel, an experienced pharmaceutical leader and pharmacist, graduate of the University of Strasbourg with an MBA (Master of Business Administration) from Noema Business School, brings with him an impressive track record in the pharmaceutical and dermo-cosmetic industry.
His international experience spans the DACH region, the USA as well as markets in Europe, Latin America, the Middle East and South East Asia with extensive knowledge in the areas of prescription drugs, over-the-counter drugs, orphan drugs, medical devices, food supplements, aesthetics and cosmetic brands.
In addition to his role as Managing Director, Pascal Voltzenlugel is a member of the Board of Directors of VIPS (Association of Pharmaceutical Companies in Switzerland) and was a member of the Board of Directors of the BPI (Federal Association of the Pharmaceutical Industry) Baden-Württemberg. He also holds the position of Administrator on the Board of Directors of the Swiss-French Chamber of Commerce.
Dr. Thomas Stiefel, co-founder of biosyn Arzneimittel GmbH, comments on the successful appointment of Pascal Voltzenlugel: “With the arrival of Pascal Voltzenlugel, a pharmaceutical expert, biosyn has found a key figure for its positive development”.
As a committed CEO with outstanding leadership qualities, expertise and comprehensive skills, Pascal Voltzenlugel is ideally prepared to further develop biosyn’s strengths and successfully master future challenges.
We congratulate Pascal Voltzenlugel on his new role and wish him every success in leading biosyn Arzneimittel GmbH.
